Why the study?
Does Recombinant Human Activated Protein C (DAA) provide benefit in adults with established and severe septic shock?
Does Recombinant Human Activated Protein C (DAA) provide benefit in adults with established and severe septic shock?
Recombinant Human Activated Protein C (DAA) showed no evidence of benefit or harm in adults with established and severe septic shock.
DAA has no role in established severe septic shock; confirms lack of benefit in this RCT and supports market withdrawal.
In adults with established and severe septic shock, DAA showed no evidence of benefit or harm. Clinical trial registered with www.clinicaltrials.gov (NCT00625209).
No takes yet. Share an insight, caveat, or question.
Annane et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: